
Industrials · Nasdaq: LIN
Linde earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 4 Feb 2027
Latest: Q3 2026
Linde reported third-quarter 2026 sales of $9.4 billion, up 9%, adjusted EPS of $4.59, up 9% YoY, and GAAP EPS of $3.66, down 11%.
Linde posted record quarterly sales of $9,404 million, up 9%, with underlying sales up 5% from 3% higher prices and 2% higher volumes. Adjusted EPS of $4.59 rose 9%, but GAAP EPS fell 11% to $3.66 after a $425 million restructuring charge. Operating cash flow was $3,169 million. Electronics and chemicals & energy drove growth, while Europe stayed flat and the Lincare home-care business remained a drag.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $8.3B * |
| Q1 2025 | $8.1B |
| Q2 2025 | $8.5B |
| Q3 2025 | $8.6B |
| Q4 2025 | $8.8B * |
| Q1 2026 | $8.8B |
| Q2 2026 | $9.3B |
| Q3 2026 | $9.4B |
Data
| Q1 2025 | $3.51 |
| Q2 2025 | $3.73 |
| Q3 2025 | $4.09 |
| Q1 2026 | $3.98 |
| Q2 2026 | $4.15 |
| Q3 2026 | $3.66 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 27.4% |
| Q1 2025 | 26.9% |
| Q2 2025 | 27.7% |
| Q3 2025 | 27.5% |
| Q4 2025 | 23.0% |
| Q1 2026 | 27.8% |
| Q2 2026 | 27.5% |
| Q3 2026 | 22.9% |
Data
| Q4 2024 | $1.6B |
| Q1 2025 | $891.0M |
| Q2 2025 | $954.0M |
| Q3 2025 | $1.7B |
| Q4 2025 | $1.6B |
| Q1 2026 | $898.0M |
| Q2 2026 | $833.0M |
| Q3 2026 | $1.8B |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.3Bd | $8.1B | $8.5B | $8.6B | $8.8Bd | $8.8B | $9.3B | $9.4B |
| Operating income | $2.3Bd | $2.2B | $2.4B | $2.4B | $2.0Bd | $2.4B | $2.6B | $2.1B |
| Operating margin | 27.4% | 26.9% | 27.7% | 27.5% | 23.0% | 27.8% | 27.5% | 22.9% |
| Net income | $1.7Bd | $1.7B | $1.8B | $1.9B | $1.5Bd | $1.9B | $1.9B | $1.7B |
| Diluted EPS | — | $3.51 | $3.73 | $4.09 | — | $3.98 | $4.15 | $3.66 |
| Operating cash flow | $2.8Bd | $2.2B | $2.2Bd | $2.9Bd | $3.0Bd | $2.2B | $2.3Bd | $3.2Bd |
| Capital expenditure | $1.2Bd | $1.3B | $1.3Bd | $1.3Bd | $1.5Bd | $1.3B | $1.4Bd | $1.4Bd |
| Free cash flow | $1.6B | $891.0M | $954.0M | $1.7B | $1.6B | $898.0M | $833.0M | $1.8B |
| R&D expense | $39.0Md | $38.0M | $38.0M | $36.0M | $35.0Md | $38.0M | $37.0M | $37.0M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-Q and 10-K filings
- 29 Oct 202610-Q for the period ended 30 Sep 2026SEC ↗
- 31 Jul 202610-Q for the period ended 30 Jun 2026SEC ↗
- 1 May 202610-Q for the period ended 31 Mar 2026SEC ↗
- 25 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 31 Oct 202510-Q for the period ended 30 Sep 2025SEC ↗
- 1 Aug 202510-Q for the period ended 30 Jun 2025SEC ↗
- 1 May 202510-Q for the period ended 31 Mar 2025SEC ↗
- 26 Feb 202510-K for the period ended 31 Dec 2024SEC ↗